Cogent Biosciences (COGT) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $5.49B and a free-cash-flow yield of -5.2%. Nama's AI scorecard rates it Sell, 2.7 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Sell · 2.7/10
Clearly negative, short of the bottom band. As of Nov 7, 2026.
Momentum
Rising · +104.8% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-27.6%
How far the last close sits under the highest price of the past five years.
Market cap
$5.49B
Trailing P/E
—
Price / book
10.2
Price / sales
—
FCF yield
-5.2%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
0.3
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
COGT earnings
Next report: Feb 16, 2027 (Q4 2026, EPS estimate -$0.58).
Beat the EPS estimate in 2 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 5, 2026
-$0.59
-$0.55
-7.3%
—
Q2 2026
Aug 10, 2026
-$0.52
-$0.56
+7.1%
$0
Q1 2026
May 5, 2026
-$0.53
-$0.54
+1.9%
$0
Q4 2025
Feb 17, 2026
-$0.56
-$0.51
-9.8%
$0
COGT analyst price target
Median target $55.00 from 11 analysts, ranging $45.00 – $62.00.
Nama's AI scorecard currently rates Cogent Biosciences Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does COGT report earnings?
Cogent Biosciences's next scheduled report is on Feb 16, 2027. Analysts expect EPS of -$0.58.
What is the COGT price target?
The median analyst price target from 11 analysts is $55.00, with a range of $45.00 – $62.00.
Is COGT Shariah compliant?
Nama's AAOIFI-style screen reads Cogent Biosciences as Can't Tell. A figure the screen needs is missing, so it can't tell.